India, April 14 -- Virax Biolabs Group Limited (VRAX), a biotechnology company, released today a shareholder letter by Chief Executive Officer James Foster, providing updates on strategic priorities and upcoming milestones.
The company is currently developing VaxImmune, a diagnostic tool for post-acute infection syndromes (PAIS) like long-COVID, post-treatment Lyme disease (PTLD), and myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS), which it believes to be underserved in the commercial market. The test is to be initially developed as a laboratory developed test (LDT), followed by development as an in vitro diagnostic (IVD) test.
The management also outlined steps to initiate entry into the U.S. market, having completed a pre...